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ABSTRACT:  
Statin therapy may lower plasma lipid concentrations, but the evidence in HIV-infected patients 
is still unclear. Therefore, we aimed to investigate the impact of statin therapy on plasma lipid 
concentrations through a systematic review of the literature and meta-analysis of available 
randomized controlled trials (RCTs). The literature search included PUBMED, SCOPUS, Web 
of Science and Google Scholar up to October 30, 2015. The meta-analysis was performed using 
either a fixed-effects or random-effect model according to I
2
 statistic. Effect sizes were expressed 
as weighted mean difference (WMD) and 95% confidence interval (CI). Two investigators 
independently reviewed the title or abstract, further reviewed the full-texts and extracted 
information on study characteristics and study outcomes. Meta-analysis of 12 RCTs with 697 
participants suggested significant reductions in plasma concentrations of low density lipoprotein 
(LDL) cholesterol (WMD: -0.72 mmol/L [-27.8 mg/dL], 95%CI: -1.04, -0.39, p<0.001; 
I
2
=85.7%), total cholesterol (WMD: -1.03 mmol/L [-39.8 mg/dL], 95%CI: -1.42, -0.64, p<0.001; 
I
2
=94.7%) and non-high density lipoprotein cholesterol (non-HDL-C) (WMD: -0.81 mmol/L [-
31.3 mg/dl], 95%CI: -1.32, -0.30, p=0.002; I
2
=76.5%), and elevations in HDL-C (WMD: 0.072 
mmol/L [2.8 mg/dL], 95%CI: 0.053, 0.092, p<0.001; I
2
=0%) following treatment with statins 
(mostly of moderate-intensity). No significant alteration in plasma triglycerides (TG) 
concentrations was found (WMD: -0.16 mmol/L [-14.2 mg/dL], 95%CI: -0.61, 0.29, p=0.475; 
I
2
=90.2%). All these effects were robust in sensitivity analysis, suggesting that the computed 
effect is not driven by any single study. In subgroup analysis, no significant difference was found 
among different statins in terms of changing plasma concentrations of LDL-C, HDL-C and TG. 
However, atorvastatin was found to be more efficacious in reducing plasma total cholesterol 
concentrations (p < 0.001). In conclusion, the meta-analysis suggested significant reductions in 
plasma concentrations of LDL-C, total cholesterol and non-HDL-C, and elevations in HDL-C, 
but no significant alteration in plasma TG following treatment with statins.  
 
 
Key words: HIV, efficacy, lipids, safety, statin therapy.   
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ABBREVIATIONS:  
ART = antiretroviral therapy  
AUC24 = 24h area under the concentration-time curve 
BMI = body mass index  
CI = confidence interval 
CYP = cytochrome  
HDL-C = high density lipoprotein cholesterol  
HIV = human immunodeficiency virus 
HMG-CoA = 3-hydroxy-3-methylglutaryl-CoA  
ICAM-1 = intracellular adhesion molecule-1  
LDL = low density lipoprotein  
LFA1 = lymphocyte function antigen-1  
non-HDL-C = non-high density lipoprotein cholesterol  
RCT = randomized controlled trial 
SD = standard deviation  
TG = triglycerides  
WMD  = weighted mean difference  
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INTRODUCTION 
In comparison with the general population, patients infected with human immunodeficiency 
virus (HIV) are 50-100% more likely to develop cardiovascular disease, despite controlling for 
major risk factors such as hypertension, cholesterol, and smoking (1). The Veterans Aging 
Cohort Study on 82,459 patients (HIV positive: n=27 350) found a 1.5-times higher risk of acute 
myocardial infarction in HIV infected patients than normal population (2). 
Despite virological suppression with antiretroviral therapy, HIV related immune activation 
and increased inflammation are associated with mortality related to cardiovascular disease (3). 
Immune activation may mediate various comorbidities, such as vascular disease, diabetes 
mellitus or high risk of arterial and venous thrombosis (4, 5). HIV infection is accompanied by 
various disturbances of plasma lipids; moreover HIV protease inhibitors, which have been shown 
to reduce hepatic clearance and increase biosynthesis of serum cholesterol, increase insulin 
resistance, centrally obesity, lipodystrophy and coronary artery calcification (6-8). As such, 
hyperlipidemia and hypertriglyceridemia are common metabolic effects of protease inhibitors (9, 
10).  
Disruption of lipid rafts due to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase 
inhibitors reduces HIV-1 particle production (11) but also inhibit lymphocyte function antigen-1 
(LFA1), down-regulate Rho activity (12), and have effects on intracellular adhesion molecule-1 
(ICAM-1), essential for viral entry and exit (13). The best choice of a pharmacologic agent for 
HIV patients taking protease inhibitors drugs might be pravastatin, which is not substantially 
metabolized by cytochrome (CYP) 3A4, decreasing the risk of hypothetic drug-drug interactions 
(14).  
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Statins could be particularly advantageous in HIV-infected individuals because of the 
pleiotropic effects of reducing inflammation and immune activation, but the findings concerning 
changes in plasma lipid parameters concentrations following statin therapy have been 
inconsistent. Therefore, in the present meta-analysis we evaluated in HIV patients, the impact of 
statin therapy on plasma lipid concentrations. 
 
METHODS  
This study was designed according to the guidelines of the 2009 preferred reporting items 
for systematic reviews and meta-analysis (PRISMA) statement (15). Due to the study design 
(meta-analysis of randomized controlled trials) no Institutional Review Board (IRB) approval, as 
well as no patients‟ informed consents were obtained.   
 
Search Strategy 
PubMed/Medline, SCOPUS, Web of Science and Google Scholar databases were searched 
using the following search terms in titles and abstracts: (Hydroxymethylglutaryl-CoA Reductase 
Inhibitors OR statin OR statins OR HMG-CoA Reductase Inhibitors OR Hydroxymethylglutaryl-
Coenzyme A Inhibitors OR Hydroxymethylglutaryl-CoA Inhibitors OR atorvastatin OR 
simvastatin OR rosuvastatin OR fluvastatin OR pravastatin OR pitavastatin OR lovastatin OR 
cerivastatin OR “statin therapy” OR statins) AND (“AIDS” OR "HIV" OR "HIV infection”) 
AND (randomized). The wild-card term „„*‟‟ was used to increase the sensitivity of the search 
strategy. The search was limited to articles published in English language. The literature was 
searched from inception to October 30, 2015. Two reviewers (MD and MCS) evaluated each 
article independently. Disagreements were resolved by discussion with a third party (MB). 
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Study Selection 
Original studies were included if they met the following criteria: (i) randomized placebo-
controlled trial (RCT) with either parallel or cross-over design, (ii) investigated the impact of 
statin therapy, either as monotherapy or combination therapy, on plasma/serum lipid 
concentrations, (iii) providing sufficient information on baseline and end-trial plasma/serum lipid 
concentrations in both statin and control groups at baseline and at the end of follow-up in each 
group or providing the net change values.  
Exclusion criteria were: (i) non-interventional trials, (ii) lack of a placebo control group for 
statin therapy, (iii) observational studies with case-control, cross-sectional or cohort design, and, 
(iv) lack of sufficient information on baseline or follow-up plasma/serum lipid concentrations. 
  
Data extraction  
 Eligible studies were reviewed and the following data were abstracted: 1) first author's 
name; 2) year of publication; 3) country where the study was performed; 4) study design; 5) 
number of participants in the statin and control groups; 6) type and dose of statin; 7) treatment 
duration; 9) age, sex and body mass index (BMI) of study participants; 9) systolic and diastolic 
blood pressures; and 10) serum/plasma concentrations of lipid parameters including total 
cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol 
(HDL-C) and triglycerides (TG). Data extraction was performed independently by 2 reviewers; 
disagreements were resolved by a third reviewer. 
  
Quality assessment 
A systematic assessment of bias in the included studies was performed using the Cochrane 
criteria (16). This involves evaluating the risk of bias as „low risk‟, „high risk or „unclear risk‟. 
8 
 
The final category implies either lack of information or doubt over the potential for bias. There 
are seven analyzed domains comprising: sequence generation (selection bias), allocation 
sequence concealment (selection bias), blinding of participants and personnel (performance 
bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), 
selective outcome reporting (reporting bias) and other potential sources of bias. 
Risk-of-bias assessment was performed independently by 2 reviewers; disagreements were 
resolved by a third reviewer. 
 
Quantitative Data Synthesis 
Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) V2 software 
(Biostat, NJ) (17). Net changes in measurements (change scores) were calculated as follows: 
measure at end of follow-up − measure at baseline. For single-arm cross-over trials, net changes 
in plasma concentrations of lipids were calculated by subtracting the value after control 
intervention from that reported after treatment. All values were collated as percent change from 
baseline in each group. Standard deviations (SDs) of the mean difference were calculated using 
the following formula: SD = square root [(SDpre-treatment)
2
 + (SDpost-treatment)
2
 – (2R × SDpre-treatment 
× SDpost-treatment)], assuming a correlation coefficient (R) = 0.5. If the outcome measures were 
reported in median and interquartile range (or 95% confidence interval [CI]), mean and standard 
SD values were estimated using the method described by Wan et al.(18). Conversion of 95% CI 
to SD was performed using the instructions of the Cochrane Handbook(16). Where standard 
error of the mean (SEM) was only reported, standard deviation (SD) was estimated using the 
following formula: SD = SEM × sqrt (n), where n is the number of subjects. 
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Net changes in measurements (change scores) were calculated for parallel and cross-over 
trials, as follows: (measure at the end of follow-up in the treatment group − measure at baseline 
in the treatment group) − (measure at the end of follow-up in the control group − measure at 
baseline in the control group). A random-effects model (using DerSimonian-Laird method) and 
the generic inverse variance method were used to compensate for the heterogeneity of studies in 
terms of study design, treatment duration, and the characteristics of populations being studied 
(19). Inter-study heterogeneity was assessed using Cochran Q test and I
2
 index. In order to 
evaluate the influence of each study on the overall effect size, sensitivity analysis was conducted 
using leave-one-out method, i.e. iteratively removing one study each time and repeating the 
analysis. 
 
Meta-regression 
A weighted random-effects meta-regression using an unrestricted maximum likelihood 
model was performed to assess the association between the overall estimates of effect size with 
duration of treatment and baseline lipid values as potential confounders. 
 
Publication bias 
Potential publication bias was explored using visual inspection of Begg‟s funnel plot 
asymmetry, Egger‟s weighted regression, and “fail safe N” tests. The Duval & Tweedie “trim 
and fill” methodwas used to adjust the analysis for the effects of publication bias (20). 
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RESULTS 
Flow and characteristics of included studies 
The initial screening for potential relevance removed articles when titles and/or abstracts 
were obviously irrelevant and did not refer to the main aim of the analysis. Among the 32 full 
text articles assessed for eligibility, 20 studies were excluded due to the lack of a control group 
(n=14), the lack of plasma lipid concentrations data (n=5) and the lack of statins (n=1) (Figure 
1). After final assessment, 12 trials achieved the inclusion criteria and were analyzed for the final 
meta-analysis (21-32).  
 
Characteristics of included studies 
In total, 697 patients in the 12 selected studies were included; 343 participants were 
allocated to statin therapy groups, and 354 served as controls. The number of participants in 
these trials ranged between 21 and 147. Included studies were published between 2001 and 2015, 
and were conducted in the USA (n=5), United Kingdom, France, Australia, Switzerland, Uganda 
and Colombia. One study was multicenter and was carried out in Australia and Switzerland. 
The following statin doses were administered in the included trials: 40 mg/day of 
pravastatin, 10 mg/day of rosuvastatin, 20 to 80 mg/day of atorvastatin and 40 mg/day of 
lovastatin. Duration of statin intervention ranged between 8 and 48 weeks. Among the 12 
included trials, 8 were designed as parallel group and 4 as crossover studies. Demographic and 
baseline parameters of the included studies are shown in Table 1. 
 
Risk of bias assessment 
An unclear risk of bias with respect to sequence generation, allocation concealment and 
blinding of outcome assessment was observed in some studies. Two trials were not blind, but 
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studies were low-risk in terms of other sources of bias. The systematic assessment of bias in the 
included studies is presented in Table 2. 
 
Effect of statin therapy on plasma lipid concentrations  
Overall, the impact of statins on plasma concentrations of total cholesterol, LDL-C, HDL-C, 
triglycerides and non-HDL-C was assessed in 10, 9, 8, 8 and 2 studies, respectively. Meta-
analysis suggested significant reductions in plasma concentrations of LDL-C (WMD: -0.72 
mmol/L [-27.8 mg/dL], 95%CI: -1.04, -0.39, p < 0.001; I
2 
= 85.7%; Figure 2), total cholesterol 
(WMD: -1.03 mmol/L [-39.8 mg/dL], 95% CI: -1.42, -0.64, p < 0.001; I
2 
= 94.7%; Figure 2) and 
non-HDL-C (WMD: -0.81 mmol/L [-31.3 mg/dl], 95% CI: -1.32, -0.30, p = 0.002; I
2 
= 76.5%; 
Figure 2), and elevations in HDL-C (WMD: 0.072 mmol/L [2.8 mg/dL], 95% CI: 0.053, 0.092, 
p < 0.001; I
2 
= 0%; Figure 2) following treatment with statins. No significant alteration in 
plasma TG concentrations was found (WMD: -0.16 mmol/L [-14.2 mg/dL], 95% CI: -0.61, 0.29, 
p = 0.475; I
2 
= 90.2%; Figure 2). All these effects were robust in sensitivity analysis, suggesting 
that the computed effect is not driven by any single study (Supplemental Figure 1). 
 
Effect of individual statins on plasma lipids and lipoproteins concentrations  
In subgroup analysis, no significant difference was found among different statins, each 
generally of moderate intensity, in terms of changing plasma concentrations of LDL-C, HDL-C 
and TG (Figure 3). However, atorvastatin was found to be more efficacious in reducing plasma 
total cholesterol concentrations (p < 0.001) (Figure 3). 
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Meta-regression 
Meta-regression analysis was conducted to evaluate the association between changes in 
plasma lipid concentrations and duration of treatment and baseline lipid values as potential 
confounders of treatment response. None of the changes in the assessed lipid parameters were 
found to be significantly associated with treatment duration (Figure 4). With respect to baseline 
values, a significant association was found for total cholesterol (slope: 0.27, 95% CI: 0.05, 0.50, 
p = 0.018), but not LDL-C, HDL-C and triglycerides (Figure 5). 
 
Publication bias 
Visual inspection of funnel plots suggested an asymmetry in the effects on plasma HDL-C 
and TG concentrations, but not LDL-C and total cholesterol. Using the “trim and fill” method, 4 
and 1 potentially missing studies were imputed for the meta-analyses of HDL-C and TG, 
respectively (Figure 6). These imputations did not change the statistical significance of the effect 
size (WMD: 0.08 mmol/L [3 mg/dL], 95% CI: 0.05, 0.10 [HDL-C] and WMD: -0.26 mmol/L 
[23 mg/dL], 95% CI: -0.70, 0.19 [TG]). 
In addition to visual inspection of funnel plots, presence of publication bias was explored 
using Begg‟s rank correlation test, Egger‟s linear regression test, and the “fail safe N” test. 
Results of these tests are shown in Supplemental Table 1. 
 
Safety of statin therapy 
Adverse events reported in the included trials are summarized in Supplemental Table 2. 
Since the exact number of subjects experiencing adverse events was not provided in most of the 
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included studies, meta-analysis comparing the safety of statin therapy versus control was not 
performed. 
 
DISCUSSIONS 
To our knowledge, this meta-analysis of RCTs is the first to assess the effect of statins on 
plasma lipid concentrations in HIV infected individuals. Data from 12 trials following treatment 
with statins suggested significant reductions in plasma concentrations of LDL-C, total 
cholesterol and non-HDL-C, and elevations in HDL-C. No significant alteration in plasma TG 
concentration was found. All these effects were robust in sensitivity analysis, suggesting that the 
computed effect is not driven by any single study. 
In the recent meta-analysis on this issue by Gili et al. (33) the efficacy and safety of different 
statins in the group of HIV-positive patients was evaluated. However, the authors included all 
available studies (both RCTs and observational), limiting the inferential strength of their data. 
Having all their available studies included, there were only 736 patients, whereas we included 
697 patients in 12 RCTs. They noticed that rosuvastatin 10 mg/day and atorvastatin 10 mg/day 
provided the largest reduction in total cholesterol levels (mean -1.67 mmol/L [-64.68 mg/dL] and 
mean -1.44 mmol/L [-55.68 mg/dL], respectively], and atorvastatin 80 mg/day and simvastatin 
20 mg/day provided the largest reduction in LDL-C [mean -2.10 mmol/L [-81.21 mg/dL] and -
1.57 mmol/L [-60.71 mg/dL], respectively]. The mean discontinuation rate observed in their 
study was 0.12 per 100 person-years and was the highest with atorvastatin 10 mg/day (26.5 per 
100 person-years) (33).  
Due to drug-drug interactions through the cytochrome enzymes, concomitant use of statins 
in the context of previous therapy with protease inhibitors needs caution (34). Indeed, most of 
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the statins interfere with metabolism of anti‐retroviral drugs due to the fact that they are 
metabolized via the cytochrome P450 3A4 isoform, inducing increased toxicity (13). These 
safety warnings have limited statin therapy in HIV-infected individuals receiving simultaneous 
antiretroviral therapy (35). Since pravastatin is a cytochrome P450 independent and water-
soluble statin it seems it might be the most advantageous on plasma lipids in HIV-infected 
individuals (36). However, Fichtenbaum et al., analyzing drug-to-drug interactions, 
demonstrated a significantly larger the median 24h area under the concentration-time curve 
(AUC24) for simvastatin and atorvastatin, while pravastatin had a decreased AUC24 when given 
concomitantly with ritonavir and saquinavir (37).  
The mechanism underlying the interactions between pravastatin and anti‐retroviral drugs 
may be due to a competition at the cytochrome level that transports protein P-glycoprotein   and 
may also be caused by genetic polymorphism (13). However, in HIV-infected patients on statin 
therapy, it has been recommended that plasma concentrations of protease inhibitors be evaluated 
to avoid drug-drug interaction (38). Current guidelines suggest that in HIV patients receiving 
protease inhibitors, fluvastatin and pravastatin are most safe to use, atorvastatin can be used at 
submaximal efficacy doses and administrated only with caution and monitoring, while lovastatin 
and simvastatin should not be used (35).  
In HIV patients, rosuvastatin, pravastatin, and pitavastatin have been reported in clinical 
trials to have satisfactory safety profiles (39). Due to the safe pharmacokinetic profile of 
pitavastatin, the Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease 
in HIV-Infected Adults (REPRIEVE) trial is an ongoing large randomized double-blind trial of 
6,500 HIV-infected patients that will evaluate the efficacy of pitavastatin 4 mg versus placebo 
for primary CVD prevention (40). The REPRIEVE trial is currently funded by the National 
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Institutes of Health's National Heart, Lung, and Blood Institute (NHLBI), National Institute of 
Allergy and Infectious Diseases (NIAID) and AIDS Clinical Trials Group (40-42). 
The present meta-analysis has several limitations. Most importantly, there were only several 
eligible RCTs, and most had relatively small numbers of patients. Furthermore, the included 
studies were heterogeneous: different statin preparations, doses, duration of treatment, study 
design, and duration of follow-up.  
In conclusion, in HIV patients, this meta-analysis suggested significant reductions in plasma 
concentrations of LDL-C, total cholesterol and non-HDL-C, and elevations in HDL-C, but no 
significant alteration in plasma TG following treatment with statins. Further large-scale, well-
designed trials are required to fully address the differential effects on statins on lipid parameters 
in the context of HIV infection.  
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TABLES LEGENDS:  
Table 1. Demographic characteristics of the included studies. 
Table 2. Risk of bias assessment in the studies included in this meta-analysis. 
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FIGURE LEGENDS:  
Figure 1. Flow chart of the number of studies identiﬁed and included into the meta-analysis. 
Figure 2. Forest plot displaying weighted mean difference and 95% confidence intervals for the 
impact of statin therapy on plasma concentrations of LDL-C, total cholesterol, HDL-C, 
triglycerides and non-HDL-C. 
Figure 3. Subgroup meta-analysis for the impact of different statins on plasma concentrations of 
lipids. 
Figure 4. Random-effects meta-regression plots of the association between mean changes in 
plasma concentrations of lipids and duration of statin treatment. 
Figure 5. Random-effects meta-regression plots of the association between mean changes in 
plasma concentrations of lipids and baseline lipid values. 
Figure 6. Funnel plot displaying publication bias in the studies reporting the impact of statin 
therapy on plasma concentrations of lipids. 
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Table 1. Demographic characteristics of the included studies. 
Study  Bonnet et 
al.(21) 
Calmy et al.(22) Eckard et 
al.(23) 
Funderbur
g et al.(24) 
Ganesan et 
al.(25) 
Hürlimannet 
al.(26) 
Lo et al. 
(27) 
Stein et 
al.(28) 
Nakanjak
oet al.(29) 
Montoya et 
al.(30) 
Moyle et 
al.(31) 
Mallon et 
al.(32) 
Year  2007 2010 2014 2015 2011 2006 2015 2004 2015 2012 2001 2006 
Location  France Australia & 
Switzerland 
USA USA USA Switzerland USA USA Uganda Colombia UK Australia 
Design  Randomize
d, double-
blind 
placebo-
controlled, 
trial 
Randomized, 
placebo 
controlled 
clinical trial 
Randomize
d, double-
blind, 
placebo-
controlled 
trial 
Randomize
d, double-
blind 
placebo-
controlled 
trial 
Randomized, 
double-blind, 
placebo-
controlled 
crossover 
trial 
Randomized, 
double blind, 
placebo 
controlled 
crossover, 
trial 
Randomized, 
double-blind, 
placebo-
controlled 
trial 
Placebo-
controlled, 
double-
blind, 
crossover 
trial 
Randomiz
ed double-
blind 
placebo-
controlled 
crossover 
trial 
Randomized, 
double-
blinded, 
placebo-
controlled 
trial 
Randomized
, open-label 
comparative 
trial 
Randomized, 
double-blind, 
placebo-
controlled 
trial 
Duration 
of trial 
 12 weeks 24 weeks 24 weeks 48 weeks 8 weeks 8 weeks 48 weeks 16 weeks 12 weeks 48 weeks 24 weeks 12 weeks 
Inclusion 
criteria 
 Patients 
were tested 
positive for 
anti-HIV 
antibodies, 
had been 
receiving 
stable 
antiretrovir
al therapy 
including at 
least one PI 
for ≥3 
months, 
had a 
plasma 
HIV RNA 
level of 
<50 
copies/mL 
for ≥3 
months 
before 
randomizat
ion, a TC 
≥5.5 
mmol/L 
with LDL-
C ≥ 3.4 
mmol/L on 
fasting 
Subcutaneous 
lipoatrophy in at 
least two body 
sites (of 
moderate or 
greater severity 
in at least one 
site) according to 
both the patient 
and their 
enrolling 
physician; stable 
antiretroviral 
therapy (ART) 
and plasma HIV 
viral load <50 
HIV-1 RNA 
copies/mL for at 
least the 
preceding 3 
months 
HIV-
infected 
adults ≥18 
years old 
who had a 
fasting LDL 
cholesterol 
level of 
≤130 mg/dL 
and either a 
hsCRP level 
of ≥2 mg/L 
and/or 
expression 
of CD38 
and HLA-
DR antigens 
on ≥19% of 
CD8+ T 
cells at 
screening, 
which 
occurred≤3
0 days 
before 
enrollment 
Patients 
aged 18 
years or 
older, 
without 
known 
coronary 
disease or 
diabetes, 
and on 
stable ART 
for at least 
3months 
and 
cumulative 
ART 
duration of 
at least 6 
months, 
with HIV-1 
RNA <1000 
copies per 
milliliter 
and fasting 
LDL-C 
≤130 mg/dL 
and fasting 
triglycerides 
≤500 mg/dL 
HIV-infected 
adults not 
receiving 
antiretroviral 
therapy 
(ART) with a 
CD4+ cell 
count >350 
cells/µL, 
HIV-1 RNA 
>1000copies/
mL, serum 
low-density 
lipoprotein 
(LDL) 
cholesterol 
level <130 
mg/dL, and 
serum 
alanine 
aminotransfe
rase and 
aspartate 
aminotransfe
rase levels, 
<1.5 times 
the upper 
limit of 
normal 
HIV 
infection, and 
protease 
inhibitor-
containing 
anti-retroviral 
combination 
therapy for at 
least four 
months, 
which was 
unchanged 
for two 
months 
Patients with 
HIV disease, 
no history of 
cardiovascul
ar disease or 
cardiac 
symptoms, 
and evidence 
of 
subclinical 
coronary 
atheroscleros
is, defined 
by presence 
of one or 
more plaques 
on CCTA 
but without 
clinically 
significant 
stenosis, 
defined as 
greater than 
50% left 
main 
stenosis or 
greater than 
70% stenosis 
in any major 
vessel 
Patients 
with HIV 
infection 
of≥6-
month 
duration, 
undergoin
g a stable 
antiretrovi
ral 
regimen 
that 
included a 
PI for at 
least 3 
months, 
LDL 
cholesterol 
levels 
>3.36 
mmol/L 
and either 
triglycerid
e levels 
>3.88 
mmol/L or 
high-
density 
lipoprotein 
(HDL) 
cholesterol 
Individual
s with 
CD4 
increase 
<295 
cells/µL 
after 
seven 
years of 
suppressiv
e cART 
Asymptomat
ic HIV-
infected 
adults who 
were 
HAART 
naive, with a 
peripheral 
blood CD4+  
T cell count 
≥350 
cells/mL and 
detectable 
viral load yet 
lower than 
100,000 
copies/mL 
 
 
Patients with 
viral load < 
500 
copies/ml 
and 
cholesterol > 
6.5 mmol/l 
(240 mg/dl) 
HIV-infected 
men (age> 
18 years) 
stable 
current PI 
therapy 
(beginning 
not less 
than12 
weeks prior 
to screening 
with little 
likelihood of 
change to the 
ART 
regimen 
expected 
during the 
study)and 
fasting 
serum total 
cholesterol > 
6.5 mmol/l  
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status after 
at least 12 
hours and 
after 3 
months of 
standardize
d dietary 
advice 
levels 
<1.07 
mmol/L. 
Statin 
form 
 Pravastatin Pravastatin Rosuvastati
n 
Rosuvastati
n 
Atorvastatin Pravastatin Atorvastatin Pravastati
n 
Pravastati
n 
Lovastatin Pravastatin Pravastatin 
Statin 
interventi
on 
 40 mg/ day 40mg/day 10 mg/day 10 mg/day 80 mg/day 40 mg/day 20/40 
mg/day 
40 mg/day 40 mg/day 40 mg/day 40mg/day 40 mg/day 
Participa
nts 
Case 12 10 67 72 22 29 17 20 15 51 14 14 
Contr
ol 
9 12 69 75 20 53 13 17 
Safety   Myalgias 
(grade 2) 
were 
recorded in 
three 
patients of 
the 
pravastatin 
group 
(including 
one with a 
two-fold 
increase of 
creatine 
phosphokin
ase 
Five participants 
(11%) developed 
sustained grade 3 
or 4 
hypertriglycerida
emia (four of 
whom had 
initiated LPV/r 
at 
screening), three 
patients 
developed a 
grade 3 or 4 
elevation 
in creatine 
kinase and one 
patient 
developed grade 
3 
thrombocytopeni
a. Two serious 
adverse events 
were reported; 
one participant 
with known 
cardiomyopathy 
was 
hospitalized for 
third-degree 
heart block at 
week 1 (uridine 
One subject 
withdrew 
because of a 
potential 
adverse 
event (on 
day 4 of 
study, grade 
2 myalgias 
caused 
the subject 
to refuse to 
continue in 
the study). 
One 
additional 
subject 
in the statin 
group 
stopped 
treatment at 
week 5 
because of 
hospitalizati
on for 
hydration 
secondary 
to grade 3 
myalgias 
without 
rhabdomyol
Two 
subjects 
withdrew 
due to grade 
2 myalgias 
with normal 
CPK levels; 
both were 
on placebo. 
One 
additional 
subject in 
the statin 
group 
stopped 
treatment at 
week 5 
because of 
hospitalizati
on for 
hydration to 
treat grade 3 
myalgias 
without 
rhabdomyol
ysis or renal 
compromise
, but 
continued to 
be followed 
on study, 
No grade 3 or 
4 
elevations in 
liver-
associated 
enzymes 
were 
observed 
during the 
study. Three 
participants 
had grade 3 
elevations in 
creatinine 
phosphokinas
e (CPK) 
levels. All 3 
participants 
reported 
myalgias 
and noted a 
temporal 
increase in 
their physical 
exercise 
regimens. 
Cessation of 
their altered 
exercise 
schedule, 
without 
Values for 
plasma 
creatinine, 
creatinine 
kinase, 
aspartate 
aminotransfer
ase, alanine 
aminotransfer
ase, and 
glucose were 
within 
normal limits 
at baseline 
and did not 
change 
during the 
study. 
Myalgias 
and liver-
function-test 
abnormalitie
s occurred in 
both 
treatment 
and placebo 
groups at 
similar rates 
without any 
differences 
in the timing 
of adverse 
events. No 
adverse 
event led to 
discontinuati
on from the 
study. One 
participant 
had myalgias 
and was 
reduced to 
10 mg, 
which was 
tolerated for 
the duration 
of the trial. 
After 
unblinding at 
One 
subject 
had an 
asymptom
atic 
increase in 
CK 
>2-times 
ULN, and 
another 
subject 
had an 
asymptom
atic 
increase in 
CK >3-
times 
ULN. 
mild 
myalgia 
developed 
in 1 
subject, 
and 
muscle 
aches 
characteriz
ed as 
“severe” 
developed 
in 2 
Myalgias 
as the 
commone
st in six 
individual
s (three in 
atorvastati
n 
and three 
in placebo 
arms), 
followed 
by chest 
pain in 
four 
individual
s (three in 
atorvastati
n and one 
in placebo 
arms), 
headache 
in four 
individual
s (one in 
atorvastati
n 
and three 
in placebo 
arms) and 
arthralgia 
Only two 
patients 
suspended 
the 
medication 
due to effects 
related to 
lovastatin: 
one due to an 
erythematous 
maculopapul
ar 
rash during 
the first 
week, and 
the second 
one 
due to the 
serum 
aminotransfe
rase 
concentratio
n higher 
than those 
allowed by 
the study 
protocol 
No episodes 
of myalgia 
or myositis 
occurred and 
creatinine 
kinase 
remained 
stable in 
both groups 
throughout 
24 weeks of 
follow-up. 
Additionally
, hepatic 
transaminase 
values did 
not 
significantly 
change, 
although 
values were 
significantly 
higher at 
baseline in 
the 
pravastatin 
group 
No 
significant 
changes in 
serum 
creatinine, 
bilirubin, 
alanine 
aminotransfe
rase or 
alkaline 
phosphatase 
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and pravastatin 
arm) and another 
participant was 
hospitalized 
for 
gastroenteritis at 
baseline (uridine 
arm). 
ysis or renal 
compromise 
but 
continued to 
be followed 
during the 
study but 
without 
receiving 
the study 
drug. 
off study 
drug, and 
myalgia 
resolved 
soon after 
study drug 
was 
discontinue
d. 
discontinuing 
treatment 
assignments, 
resulted in 
resolution of 
the CPK 
elevations 
and 
symptoms. 
the 
conclusion 
of the study, 
this 
participant 
had received 
atorvastatin. 
A second 
participant 
had a dose 
reduction 
from 40 mg 
back to 20 
mg because 
of a rise in 
alanin 
aminotransfe
rase 
subjects. in three 
individual
s 
(two in 
atorvastati
n and one 
in placebo 
arm). 
Other 
expected 
adverse 
events 
included 
backache 
(1), 
neck pain 
(1), left 
forearm 
pain (1); 
only 
reported 
in the 
atorvastati
n arm) 
Age 
(years) 
Case 42 (39–47) 46 (42-57) 45.6 (41.1–
51.4) 
45.6 (41.1–
51.4) 
30 (25–38) 43* 52.2±3.8 44.1±1.6 41 (40–
50) 
32 (26-39) NS 52±12 
Contr
ol 
41 (38-50) 47 (44-52) 46.9 (39.2–
53.6) 
46.9 (39.2–
53.6) 
30 (25–38) 50.0±5.6 47 (43–
51) 
31 (27-38) NS 43±9 
Male (%) Case 92 100 81 81 100 79 79 90 53.3 87 100 100 
Contr
ol 
78 100 76 76 100 79 81 90 33.3 84 100 100 
BMI 
(kg/m2) 
Case NS 24 (24-25) 26.6 (23.4–
30.0) 
26.6 (23.4–
30.0) 
NS 22.9 (21.4–
25.1) 
25.6±2.9 NS 20.8 
(19.5–
21.6) 
NS 23.1 (21.7-
24.4) 
24±1.0 
Contr
ol 
NS 24 (21-26) 27.2 (23.5–
30.5) 
27.2 (23.5–
30.5) 
NS 22.9 (21.4–
25.1) 
25.8±4.8 NS 24.0 
(21.1–
26.4) 
NS 23.6 (21.9-
25.3) 
25±3.5 
SBP 
(mmHg) 
Case NS NS 122 (112–
136) 
122 (112–
136) 
NS 120 (114–
128) 
117±13 125.4±3.2 110 (100–
149) 
NS NS 130±14 
Contr
ol 
NS NS 120 (110–
132) 
120 (110–
132) 
NS 120 (114–
128) 
119±16 125.4±3.2 140 (112– 
163) 
NS NS 120±12 
DBP 
(mmHg) 
Case NS NS 79 (73–85) 79 (73–85) NS 77 (71–83) 73±8 NS 74 (65–
82) 
NS NS 70±15 
31 
 
Contr
ol 
NS NS 80 (72–83) 80 (72–83) NS 77 (71–83) 76±10 NS 74 (65–
82) 
NS NS 80±14 
 
 
 
 
Total 
Cholester
ol 
 
(mmol/L)/ 
mg/dl 
Case 6.1 (5.8–
6.3) / 
235,52 
(223,94-
243,24) 
5.6 (4.5-6.4) / 
216,21 (173,74-
247,10) 
NS NS 4.34 (3.72–
4.45) / 
167,57 
(143,62-
171,81) 
6.4 (6.0–7.4) 
/ 247,10 
(231,66-
285,71) 
5.14±0.98 / 
198,45±37,8
3 
5.58±0.40 
/ 
215,44±15
,44 
NS NS 7.5 (6.7±8.3) 
/ 289,58 
(258,69±320
,46) 
7.6±1.7 / 
293,44±65,6
4 
Contr
ol 
6.4 (6.1–
7.7) / 
247,10 
(235,58-
297,29) 
5.6 (4.6-6.2) / 
216,21 (177,60-
239,38) 
NS NS 4.34 (3.72–
4.45) / 
167,57 
(143,63-
171,81) 
6.4 (6.0–7.4) 
/ 247,10 
(231,66-
285,71) 
4.97±0.70 / 
191,89±27,0
2) 
5.58±0.40 
/ 
215,44±15
,44 
NS NS 7.4 (6.8±7.9) 
/ 285,71 
(262,55±305
,02) 
7.6±1.4 / 
293,44±54,0
5 
 
 
 
 
 
LDL-C 
 
(mmol/L) 
/mg/dl 
Case 4.1 (3.7–
4.6) / 
158,30 
(142,86-
177,60) 
2.8 (2.4-3.3) / 
108,10 (92,66-
127,41) 
2.48 (1.96-
2.77) / 
95,75 
(75,67-
106,95) 
NS 2.50 (2.25–
2.82) / 96,52 
(86,87-
108,88) 
3.7 (2.8–4.2) 
/ 142,86 
(108,10-
162,16) 
3.20±0.95 / 
123,55±36,6
8) 
3.47±0.32 
/ 
133,97±12
,35 
3.1 (2.2-
4.9) / 
119,69 
(84,94-
189,19) 
2.63(2.20-
3.28) 
 
 
101,54(84,94
-126,64) 
4.65 
(4.1±5.2) / 
179,53 
(158,30±200
,77) 
NS 
Contr
ol 
3.9 (3.7–
4.8) / 
150,58 
(142,85-
185,33) 
3.5 (2.5-4.1) / 
135,13 (96,52-
158,30) 
2.50 (1.99-
3.13) / 
96,52 
(76,83-
120,84) 
NS 2.50 (2.25–
2.82) / 96,52 
(86,87-
108,88) 
3.7 (2.8–4.2) 
/ 142,85 
(108,10-
162,16) 
3.23±0.83 / 
124,71±32,0
4 
3.47±0.32 
/ 
133,97±12
.35 
4.9 (2.4-
6.7) / 
189,19 
(92,66-
258,68) 
2.53 (2.30-
3.10) / 97,68 
(88,80-
119,69) 
4.68 
(3.89±5.47) / 
180,69 
(150,19±211
,19) 
NS 
 
 
 
HDL-C 
 
 
(mmol/L) 
/mg/dl 
Case 
 
 
 
 
0.9 (0.8–
1.1) / 34,74 
(30,88-
42,47) 
1 (0.9-1.3) / 
38,61 (34,74-
50,19) 
NS 1.21 (0.98-
1.49) / 
46,71 
(37,84-
57,53) 
NS 1.2 (1.1–1.6) 
/ 46,33 
(42,47-61,77) 
1.34±0.50 / 
51,74±19,30 
0.94±0.07 
/ 
36,29±2,7
0 
1.7 (1.6-
1.8) / 
65,63 
(61,77-
69,49) 
NS 0.94 
(0.79±1.08) / 
36,29 
(30,50±41,6
9) 
1.1±0.4 / 
42,47±15,44 
Contr
ol 
1.0 (0.8–
1.1) / 38,61 
(30,88-
42,47) 
1.1 (0.81-1.2) / 
42,47 (31,27-
46,33) 
NS 1.19 (0.96-
1.47) / 
45,94 
(37,06-
56,75) 
NS 1.2 (1.1–1.6) 
46,33 / 
(42,47-61,77) 
1.31±0.39 / 
50,57±15,05
8) 
0.94±0.07 
/ 
36,29±2,7
0 
1.7 (1.5-
2.0) / 
65,63 
(57,91-
77,22) 
NS 0.87 
(0.72±1.02) / 
33,59 
(27,79±39,3
8) 
1.1±0.4 / 
42,47±15.44) 
 
 
 
Triglyceri
des 
 
(mmol/L) 
/mg/dl 
Case 2.0 (1.1–
3.3) / 177 
(97,35-
292,05) 
3.9 (2.0-6.2) / 
345,15 (177-
548,7) 
NS NS NS 3.0 (2.1–4.0) 
/ 265,5 
(185,85-354) 
1.36 (1.10-
2.31) / 
120,36 
(97,35-
204,43) 
3.78±0.67 
/ 
334,53±59
,29 
1.6 (1.1-
2.4) / 
141,6 
(97,35-
212,4) 
NS 3.96 
(2.84±6.52) / 
350,46 
(251,34±577
,02) 
3.8±4.1 / 
336,3±362,8
5 
Contr
ol 
3.2 (2.1–
4.4) / 283,2 
(185,85-
389,4) 
2.3 (1.5-3.5) / 
203,55 (132,75-
309,75) 
NS NS NS 3.0 (2.1–4.0) 
/ 265,5 
(185,85-354) 
1.28 (1.04-
1.53) / 
113,28 
(92,04-
135,40) 
3.78±0.67 
/ 
334,53±59
,29 
2.0 (1.4-
3.2) / 177 
(123,9-
283,2) 
NS 4.06 
(2.20±5.97) / 
359,31 
(194,7±528,
34) 
4.9±7.8 / 
433,65±690,
3 
Non-
HDL-C 
(mmol/L) 
/mg/dl 
Case NS NS NS NS NS NS NS 4.64±0.37 
/ 
179,15±14
,28 
NS NS NS 6.3±1.8 / 
243,24±69,4
9 
32 
 
Contr
ol 
NS NS NS NS NS NS NS 4.64±0.37 
/ 
179,15±14
,28 
NS NS NS 6.5±1.9 / 
251.35±73.4
7 
 
Values are expressed as mean ± SD or median (interquartile range);*only median. 
ABBREVIATIONS: SD: standard deviation; BMI: body mass index; NS: not stated; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein 
cholesterol; SBP: systolic blood pressure; DBP: diastolic blood pressure; hs-CRP: high-sensitivity C-reactive protein; cART: combination antiretroviral therapy; HAART: 
highly active antiretroviral therapy; PI: protease inhibitors; CCTA: CT angiography 
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Table 2. Risk of bias assessment in the studies included in this meta-analysis. 
Study SEQUENCE 
GENERATION 
  
ALLOCATION 
CONCEALMENT 
  
BLINDING OF 
PARTICIPANTS 
AND PERSONNEL  
BLINDING OF 
OUTCOME 
ASSESSMENT 
  
INCOMPLETE 
OUTCOME 
DATA 
  
SELECTIVE 
OUTCOME 
REPORTING 
  
OTHER 
POTENTIAL 
THREATS TO 
VALIDITY  
Bonnetet 
al.2007(21) 
L L L U L L L 
Calmyet 
al.2010(22) 
L L H U L L L 
Eckardet 
al.2014(23) 
U U L L L L L 
Funderburget 
al. 2015(24) 
L L L U L L L 
Ganesanet al. 
2011(25) 
U U L L L L L 
Hürlimannet 
al. 2006(26) 
U U L U L L L 
Loet 
al.2015(27) 
L L L L L L L 
Steinet al. 
2004(28) 
U U L U L L L 
Nakanjakoet 
al. 2015(29) 
L L L L L L L 
Montoya et al. 
2012(30) 
L L L L L L L 
Moyle et al. 
2001(31) 
L L H H L L L 
Mallon et al. 
2006(32) 
U L L U L L L 
 
L: low risk of bias; H: high risk of bias; U: unclear risk of bias. 
 
 
